Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.
OBJECTIVE Statins are known to reduce CRP concentrations , but whether high doses are more effective is not known . METHODS In a prospect i ve double-blind multicenter study in 186 DM2 patients without manifest coronary artery disease and with dyslipidemia , the effect of a 30-week treatment with 10 and 80 mg atorvastatin or placebo on the reduction of hs-CRP levels was measured . RESULTS Median CRP levels increased with 6.6 % in the placebo group and were reduced by 15 and 47 % , respectively , with atorvastatin 10 and 80 mg ( P<0.001 ; significantly different from 10 mg atorvastatin and from placebo ( P<0.001 ) . Variation in IL-6 and plasma lipids associated for 21 and 8 % , respectively , with variation in CRP levels ( P<0.001 and P=0.01 ) . Of patients with a baseline CRP level above an arbitrary threshold of 3.0 mg/l , 56 % in the 80 mg atorvastatin group reached a level of less than 3.0 mg/l , versus 23 % r and omized to 10 mg atorvastatin ( P<0.01 ) and 17 % in the placebo group ( P<0.005 ) . CONCLUSIONS In DM2 patients high dose atorvastatin induced a strong reduction in CRP levels . The decrease in CRP was mainly independent of effects on lipid lowering and changes in IL-6 levels . The pleiotropic effect of high-dose atorvastatin on inflammation could add to its cardioprotective effect in high-risk patients
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .